CDK12突变晚期前列腺癌的临床结局
CDK12突变患者至转移时间(中位34.9个月,p=0.004)和至去势抵抗时间(中位32.7个月,p<0.001)更短,一线ARPI治疗后PSA进展时间也更短(中位3.6个月,p=0.0219)。
要点
- CDK12突变晚期前列腺癌至转移时间中位34.9个月,较短。
- CDK12突变至去势抵抗时间中位32.7个月,较短。
- 一线ARPI治疗mCRPC后PSA进展时间中位3.6个月,较短。
核心结论
- CDK12突变晚期前列腺癌表现出更具侵袭性的临床行为。
- 需进一步明确不同分子亚型的特征及合适治疗策略。
研究设计与样本
- 三个学术医学中心的回顾性分析,纳入317例晚期前列腺癌患者。
- 肿瘤组织测序172例,循环肿瘤DNA测序145例。
- 按突变状态分层:CDK12、同源重组缺陷(HRD;BRCA1/2和ATM)、TP53及其他队列。
- 采用Kaplan-Meier法评估至转移、至去势抵抗及一线ARPI治疗后PSA进展时间。
主要发现
- 中位随访66.6个月。
- CDK12突变患者至转移时间中位34.9个月(p=0.004),较其他基因组亚型短。
- CDK12突变患者至去势抵抗时间中位32.7个月(p<0.001),较其他基因组亚型短。
- CDK12突变患者一线ARPI治疗mCRPC后PSA进展时间中位3.6个月(p=0.0219)。
- CDK12突变患者总治疗时间与其他突变亚组相比无整体缩短,多因素分析中CDK12状态无统计学显著性。
关键数值与推荐
- CDK12突变组至转移时间中位34.9个月(p=0.004)。
- CDK12突变组至去势抵抗时间中位32.7个月(p<0.001)。
- CDK12突变组一线ARPI治疗后PSA进展时间中位3.6个月(p=0.0219)。
临床怎么用
- CDK12突变晚期前列腺癌可能需考虑治疗强化或联合方案。
- 应充分刻画不同晚期前列腺癌亚型的分子和临床特征。
局限性
- 不同中心的实践模式存在差异。
- 合并肿瘤组织与液体活检数据导致异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cyclin-dependent kinase 12 (CDK12) loss occurs in 3-7% of metastatic prostate cancer patients and is characterized by a genomic instability signature, but the clinical implications of CDK12 loss are not well established. OBJECTIVE: To determine the clinical course of patients with CDK12 mutant advanced prostate cancer compared with other genomic subtypes. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of data from three academic medical centers, including 317 patients with advanced prostate cancer and prior next-generation sequencing from tumor tissue (n = 172) or circulating tumor DNA (n = 145), was performed. Forty-six patients had CDK12 mutations; 34 had biallelic CDK12 loss (79%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were stratified by mutation status (CDK12, homologous recombination deficiency [HRD; BRCA1/2 and ATM], TP53, and other cohort). The Kaplan-Meier method was used to evaluate time to event outcomes: time to development of metastatic disease, time to development of castration resistance, and time to prostate-specific antigen (PSA) progression after first-line androgen receptor pathway inhibitor (ARPI) therapy in a patient subset. RESULTS AND LIMITATIONS: The median follow-up was 66.6 mo. Patients with CDK12 mutant prostate cancer exhibited shorter time to metastasis (median = 34.9 mo, p = 0.004) and development of castration-resistant disease (median = 32.7 mo, p < 0.001), compared with other genomic subtypes, with shorter time to PSA progression on first-line ARPI treatment of metastatic castration-resistant disease (median = 3.6 mo, p = 0.0219). CDK12 mutant patients did not have overall shorter time on treatment compared with other mutation subgroups, and CDK12 status did not demonstrate statistical significance in multivariate analysis. Limitations include variable center-dependent practice patterns and heterogeneity due to combining tumor and liquid biopsy data. CONCLUSIONS: Our data suggest that advanced prostate cancers harboring CDK12 mutations display aggressive clinical behavior, underscoring the need to fully delineate the molecular and clinical characteristics, and appropriate therapeutic approaches for distinct subtypes of advanced prostate cancers. PATIENT SUMMARY: In this report, we evaluate the clinical characteristics and outcomes of patients with prostate cancer and CDK12 mutation in their tumors. These patients seem to have more aggressive disease, with more high-grade Gleason ≥8 cancers and shorter time to developing metastatic cancer. Cases of advanced CDK12-mutated prostate cancer may warrant consideration of therapy intensification or combination approaches.
引用
- Reimers MA, Yip SM, Zhang L, et al. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2019. PMID: 31640893. doi:10.1016/j.eururo.2019.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。